Page 85 - GPD-4-2

Gene & Protein in Disease Alport syndrome: Genetics, variability, and management

nephroprotective therapy with ramipril in children with doi: 10.1016/j.kint.2016.02.018
Alport’s syndrome. Kidney Int. 2020;97(6):1275-1286.
42. Study Details - Study of Sparsentan Treatment in Pediatrics
doi: 10.1016/J.KINT.2019.12.015 With Proteinuric Glomerular Disease. Available from:
https://clinicaltrials.gov/study/nct05003986 [Last accessed
33. Kashtan CE, Gross O. Clinical practice recommendations
for the diagnosis and management of Alport syndrome in 2024 Dec 14].
children, adolescents, and young adults-an update for 2020. 43. Kim SG, Akinfolarin AA, Inker LA, et al. WCN23-1117
Pediatr Nephrol. 2021;36(3):711-719. atrasentan in patients with proteinuric glomerular diseases-
the affinity study. Kidney Int Rep. 2023;8(9):1902.
doi: 10.1007/S00467-020-04819-6/METRICS
doi: 10.1016/j.ekir.2023.02.1089
34. Gross O, Friede T, Hilgers R, et al. Safety and efficacy of
the ace-inhibitor ramipril in alport syndrome: The double- 44. Komers R, Coppo R, Masthan Ahmed NA, et al. WCN24-
blind, randomized, placebo-controlled, multicenter phase 774 preliminary findings from the phase 2 eppik study of
III early PRO-Tect alport trial in pediatric patients. ISRN sparsentan in pediatric patients with selected proteinuric
Pediatr. 2012;2012:436046. glomerular diseases. Kidney Int Rep. 2024;9(4):S142-S143.
doi: 10.5402/2012/436046 doi: 10.1016/J.EKIR.2024.02.294
35. Zhu Z, Rosenkranz KAT, Kusunoki Y, et al. Finerenone 45. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis,
added to RAS/SGLT2 blockade for CKD in Alport syndrome. lipotoxicity and the metabolic syndrome. Biochim Biophys
Results of a randomized controlled trial with Col4a3/mice. Acta (BBA) Mol Cell Biol Lipids. 2010;1801(3):209-214.
J Am Soc Nephrol. 2023;34(9):1513-1520. doi: 10.1016/J.BBALIP.2009.10.006
doi: 10.1681/ASN.0000000000000186 46. Merscher S, Pedigo CE, Mendez AJ. Metabolism, energetics,
36. Study Details - A Study to Learn More About How Well the and lipid biology in the podocyte - cellular cholesterol-
Study Treatment Finerenone Works, How Safe it is, How it mediated glomerular injury. Front Endocrinol (Lausanne).
Moves Into, Through, and Out of the Body, and the Effects 2014;5:169.
it Has on the Body When Taken With an ACE Inhibitor or doi: 10.3389/FENDO.2014.00169
Angiotensin Receptor Blocker in Children With Chronic
Kidney Disease and Proteinuria. Available from: https:// 47. Mitrofanova A, Molina J, Varona Santos J, et al.
clinicaltrials.gov/study/NCT05196035#participation- Hydroxypropyl-β-cyclodextrin protects from kidney disease
criteria [Last accessed on 2024 Dec 14]. in experimental Alport syndrome and focal segmental
glomerulosclerosis. Kidney Int. 2018;94(6):1151-1159.
37. Yamamura T, Horinouchi T, Nagano C, et al. Genotype-
phenotype correlations influence the response to angiotensin- doi: 10.1016/J.KINT.2018.06.031
targeting drugs in Japanese patients with male X-linked 48. Study Details - Study to Evaluate R3R01 in Patients With
Alport syndrome. Kidney Int. 2020;98(6):1605-1614. Alport Syndrome and Patients With Focal Segmental
doi: 10.1016/J.KINT.2020.06.038 Glomerulosclerosis. Available from: https://clinicaltrials.gov/
study/NCT05267262 [Last accessed on 2024 Dec 14].
38. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin,
cardiovascular outcomes, and mortality in type 2 diabetes. 49. Rao IR, Kolakemar A, Shenoy SV, et al. Hydroxychloroquine
N Engl J Med. 2015;373(22):17-18. in nephrology: Current status and future directions.
J Nephrol. 2023;36(8):2191-2208.
doi: 10.1056/NEJMOA1504720
doi: 10.1007/S40620-023-01733-6
39. Boeckhaus J, Gale DP, Simon J, et al. SGLT2-
inhibition in patients with alport syndrome. Kidney Int 50. Chavez E, Rodriguez J, Drexler Y, Fornoni A. Novel therapies
Rep. 2024;9(12):3490-3500. for alport syndrome. Front Med (Lausanne). 2022;9:848389.
doi: 10.1016/J.EKIR.2024.09.014 doi: 10.3389/FMED.2022.848389/BIBTEX
40. Gross O, Boeckhaus J, Weber LT, et al. Protocol and rationale 51. Schrezenmeier E, Dörner T. Mechanisms of action of
for a randomized controlled SGLT2 inhibitor trial in hydroxychloroquine and chloroquine: Implications for
paediatric and young adult populations with chronic kidney rheumatology. Nat Rev Rheumatol. 2020;16:1-12.
disease: Double PRO-Tect Alport. Nephrol Dial Transplant. doi: 10.1038/s41584-020-0372-x
2024;40:679-687.
52. Sun L, Kuang XY, Zhang J, Huang WY. Hydroxychloroquine
doi: 10.1093/NDT/GFAE180 ameliorates hematuria in children with X-linked alport
41. Dufek B, Meehan DT, Delimont D, et al. Endothelin A syndrome: Retrospective Case series study. Pharmgenomics
receptor activation on mesangial cells initiates Alport Pers Med. 2023;16:145.
glomerular disease. Kidney Int. 2016;90(2):300-310. doi: 10.2147/PGPM.S394290

Volume 4 Issue 2 (2025) 11 doi: 10.36922/gpd.7656